The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis

Myers, Julie; Wielage, Ronald C; Han, Baoguang; Price, Karen; Gahn, James; Paget, Marie-Ange; Happich, Michael

doi:10.1186/1471-2474-15-76

Table 3 Quality assessment of included articles

From: The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis

Study	Randomization appropriate^a	Treatment allocation concealment^b	Groups similar at baseline^c	Blinding of all participants^d	Unexpected imbalance in drop-outs^e	Measured outcomes not reported^f	ITT analysis, missing data^g	Quality score^h
Abou-Raya et al. 2012 [49]	Yes	Yes	Yes	Yes	No	No	Yes	7
Afilalo et al. 2010 [50]	Yes	Yes	Yes	Yes	No	No	Yes	7
Baerwald et al. 2010 [51]	Not clear	Not clear	Yes	Yes	No	No	Yes	5
Bensen et al. 1999 [52]	Yes	Yes	Yes	Yes	No	No	Yes	7
Bingham et al. 2007 [53]	Not clear	Not clear	Yes	Yes	No	No	Yes	5
Boswell et al. 2008 [54]	Not clear	Not clear	Yes	Yes	No	No	Yes	5
Burch et al. 2007 [55]	Yes	Yes	Yes	Yes	No	No	Not clear	6
Chappell et al. 2011 [26]	Yes	Yes	Yes	Yes	No	No	Yes	7
Chappell et al. 2009 [27]	Yes	Yes	Yes	Yes	No	No	Yes	7
Clegg et al. 2006 [56]	Yes	Yes	Yes	Yes	No	No	Yes	7
DeLemos et al. 2011 [57]	Not clear	Yes	Yes	Yes	No	No	Yes	6
Essex et al. 2012 [58]	Yes	Yes	Yes	Yes	No	No	Yes	7
Fishman et al. 2007 [59]	Yes	Yes	Yes	Yes	Yes, explained	No	Yes	6
Fleischmann et al. 2006 [60]	Not clear	Yes	Yes	Yes	No	No	Yes	6
Fleischmann et al. 2001 [61]	Yes	Yes	Yes	Yes	No	No	Yes	7
Gana et al. 2006 [36]	Yes	Yes	Yes	Yes	No	No	Yes	7
Hochberg et al. 2011 [62]	Yes	Yes	Yes	Yes	No	No	Yes	7
Kivitz et al. 2002 [63]	Yes	Yes	Yes	Yes	No	No	Yes	7
Kivitz et al. 2001 [64]	Yes	Yes	Yes	Yes	No	No	Yes	7
Lehmann et al. 2005 [65]	Yes	Yes	Yes	Yes	No	No	Yes	7
Leung et al. 2002 [66]	Yes	Yes	Yes	Yes	No	Yes	Not clear	5
Markenson et al. 2005 [67]	Yes	Yes	Yes	Yes	No	No	Yes	7
Puopolo et al. 2007 [68]	Yes	Not clear	Yes	Yes	No	No	Not clear	5
Rauck et al. 2013 [69]	not clear	Yes	Yes	Yes	No	No	Yes	6
Schnitzer et al. 2011 [70]	Yes	Yes	Yes	Yes	No	No	Yes	7
Schnitzer et al. 2011 [71]	Not clear	Not clear	Yes	Yes	No	No	Yes	5
Schnitzer et al. 2010 [72]	Yes	Not clear	Yes	Yes	No	No	Yes	6
Sheldon et al. 2005 [73]	Yes	Yes	Yes	Yes	No	No	Yes	7
Sowers et al. 2005 [74]	Yes	Not clear	Yes	Yes	No	No	Yes	6
Tannenbaum et al. 2004 [75]	Not clear	Yes	Yes	Yes	No	No	Yes	6
Vojtassak et al. 2011 [76]	Yes	Yes	Yes	Yes	No	No	Yes	7
Wiesenhutter et al. 2005 [77]	Not clear	Yes	Yes	Yes	No	No	Yes	6

^a“Was randomisation carried out appropriately?”.
^b“Was the concealment of treatment allocation adequate?”.
^c“Were the groups similar at the outset of the study in terms of prognostic factors, for example, severity of disease?”.
^d“Were the care providers, participants and outcome assessors blind to treatment allocation? If any of these people were not blinded, what might be the likely impact on the risk of bias (for each outcome)?”.
^e“Were there any unexpected imbalances in drop-outs between groups? If so, were they explained or adjusted for?”.
^f“Is there any evidence to suggest that the authors measured more outcomes than they reported?”.
^g“Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data?”.
^hQuality Score is calculated by summing the positive answers to each question (“yes” answers to questions 1–4 and 7, and “no” answers to questions 5 &6).

Back to article page

ISSN: 1471-2474

Contact us

Submission enquiries: bmcmusculoskeletaldisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Musculoskeletal Disorders

Contact us